ethoxyethyl isopropyl ether | 18854-32-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethoxyethyl isopropyl ether
• 英文别名: 1-ethoxy-2-isopropoxy-ethane；Aethylenglykol-aethylaether-isopropylaether；1-Aethoxy-2-isopropoxy-aethan；Aethylenglycolaethylisopropylaether；1-Ethoxy-2-(1-methylethoxy)ethane；2-(2-ethoxyethoxy)propane
• CAS: 18854-32-5
• 化学式: C₇H₁₆O₂
• 分子量: 132.203
• InChiKey: WHRXYZCLPICICK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,8-Dibromo-2-brommethyl-3,6-dioxaoctan 生成 ethoxyethyl isopropyl ether
  参考文献：
  名称：

  Movsumzade,M.M. et al., Journal of Organic Chemistry USSR (English Translation), 1972, vol. 8, p. 1578

  摘要：

  DOI：

文献信息

• Preparation and use of compounds as protease inhibitors
  申请人：Stamford Andrew

  公开号：US20080176868A1

  公开（公告）日：2008-07-24

  Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Q is a bond or —N(R 5 )—; T is a bond, —O—, —C(O)—; S, —N(R 5 )—, or —C(R 6′ R 7′ ); U is a bond or —C(R 6 )(R 7 )— Y is C or N; Z is C or N; ring A, including variables Y and Z, is a three to nine membered cycloalkyl, cycloalkenyl, heterocylcyl, heterocyclenyl, aryl, and heteroaryl ring having 0 to 4, preferably 0 to 2, heteroatoms independently selected from the group consisting of O, S, N and —N(R)—, wherein ring A is unsubstituted or substituted with 1 to 5 independently selected R 1 moieties and/or oxo when ring A is cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl; and R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 6 , R 7 and R 7′ are as defined in the specification; pharmaceutical compositions comprising the compounds of formula I and the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases.

  本公开了具有以下式I的化合物或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中Q是键或—N(R5)—；T是键，—O—，—C(O)—；S，—N(R5)—，或—C(R6′R7′)；U是键或—C(R6)(R7)；Y是C或N；Z是C或N；环A，包括变量Y和Z，是一个有0到4个，优选0到2个杂原子的三至九元环烷基、环烯基、杂环烷基、杂环烯基、芳基和杂芳基环，所述杂原子独立地选自O、S、N和—N(R)—的群，其中环A是未取代的或取代的，当环A是环烷基、环烯基、杂环烷基或杂环烯基时，取代有1到5个独立选择的R1基团和/或氧化物；以及R、R1、R2、R3、R4、R5、R6、R6、R7和R7'如规范中定义；包括具有式I的化合物的药物组合物和抑制天冬氨酸蛋白酶的方法，特别是治疗心血管疾病、认知和神经退行性疾病的方法。
• ASPARTYL PROTEASE INHIBITORS
  申请人：Wu Yusheng

  公开号：US20070287692A1

  公开（公告）日：2007-12-13

  Disclosed are compounds of formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R 1 , R 2 , R 6 , R 7 , R 30 and R 31 are as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m 1 agonist or m 2 antagonist.

  本文披露了化合物I的结构，或其立体异构体、互变异构体、或其药用可接受的盐或溶剂，其中U、W、X、R1、R2、R6、R7、R30和R31如规范中所述。此外，还披露了抑制天冬氨酸蛋白酶的方法，特别是治疗心血管疾病、认知和神经退行性疾病的方法。还披露了使用化合物I的方法治疗认知或神经退行性疾病，其中与胆碱酯酶抑制剂或肌胆碱m1激动剂或m2拮抗剂结合使用。
• Macrocyclic heterocyclic aspartyl protease inhibitors
  申请人：Iserloh Ulrich

  公开号：US20060281729A1

  公开（公告）日：2006-12-14

  Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt, solvate or ester thereof, wherein U, W, X, L, Y, M, Z, c, d, e, f, g, h, s, t, R 1 , R 2 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and R 18 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m 1 agonist or m 2 antagonist.

  揭示了公式I的化合物或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或酯，其中U、W、X、L、Y、M、Z、c、d、e、f、g、h、s、t、R1、R2、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和R18如规范中定义；以及包括公式I化合物的药物组合物。还公开了一种抑制天冬氨酸蛋白酶的方法，特别是治疗心血管疾病、认知和神经退行性疾病的方法。还公开了使用公式I化合物结合胆碱酯酶抑制剂或肌碱m1激动剂或m2拮抗剂治疗认知或神经退行性疾病的方法。
• 一种烷基双醚类化合物的制备方法
  申请人：中国石油化工股份有限公司

  公开号：CN106928032A

  公开（公告）日：2017-07-07

  本申请涉及烷基双醚类化合物的合成领域，提供了一种结构如式(I)所示的烷基双醚类化合物的制备方法，该方法包括：在浓硫酸存在下，将结构如式(II)所示的乙二醇类化合物和C2-C8的烯烃接触反应。采用本发明的制备方法所制备的烷基双醚类化合物纯度高，杂质含量低，同时制备工艺简单，采用浓硫酸作为催化剂代替传统的醇钠合成方法，安全性高，普适性较强。其中，R1和R2各自独立地为C1-C8的烷基，且R1与R2不同时为甲基；R’1为氢或C1-C8的烷基。
• Heterocyclic aspartyl protease inhibitors
  申请人：Zhu Zhaoning

  公开号：US20080200445A1

  公开（公告）日：2008-08-21

  Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O) 2 —, —C(═O)—, —O—, —C(R 6 )(R 7 )—, —N(R 5 )— or —C(═N(R 5 ))—; X is —O—, —N(R 5 )— or —C(R 6 )(R 7 )—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O) 2 —, —C(═O)— or —C(═NR 5 )—; U is a bond, —S(O)—, —S(O) 2 —, —C(O)—, —O—, —P(O)(OR 15 )—, —C(═NR 5 )—, —(C(R 6 )(R 7 )) b — or —N(R 5 )—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, U is not —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—; provided that when X is —N(R 5 )— and W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, then U is not a bond; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula 1. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m 1 agonist or m 2 antagonist.

  本发明涉及公式I的化合物或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中W是键，—C(═S)—，—S(O)—，—S(O)2—，—C(═O)—，—O—，—C(R6)(R7)—，—N(R5)—或—C(═N(R5))—；X是—O—，—N(R5)—或—C(R6)(R7)—；但当X为—O—时，U不是—O—，—S(O)—，—S(O)2—，—C(═O)—或—C(═NR5)—；U是键，—S(O)—，—S(O)2—，—C(O)—，—O—，—P(O)(OR15)—，—C(═NR5)—，—(C(R6)(R7))b—或—N(R5)—；其中b为1或2；但当W为—S(O)—，—S(O)2—，—O—或—N(R5)—时，U不是—S(O)—，—S(O)2—，—O—或—N(R5)—；当X为—N(R5)—且W为—S(O)—，—S(O)2—，—O—或—N(R5)—时，U不是键；R1、R2、R3、R4、R5、R6和R7如规范中所定义；以及包括公式1的化合物的药物组合物。本发明还涉及抑制天冬氨酸蛋白酶的方法，特别是治疗心血管疾病、认知和神经退行性疾病的方法，以及抑制人类免疫缺陷病毒、贫血原虫、D蛋白酶和原虫酶的方法。本发明还涉及使用公式I的化合物与胆碱酯酶抑制剂或肌动蛋白m1受体激动剂或m2受体拮抗剂相结合治疗认知或神经退行性疾病的方法。